DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,034 filers reported holding DANAHER CORPORATION in Q1 2023. The put-call ratio across all filers is 0.99 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $826,505,000 | -5.5% | 3,331,336 | -8.6% | 0.22% | -2.2% |
| Q2 2023 | $874,763,000 | -32.1% | 3,644,845 | -28.7% | 0.23% | -37.1% |
| Q1 2023 | $1,288,215,000 | -34.6% | 5,111,144 | -31.1% | 0.36% | -35.5% |
| Q4 2022 | $1,968,925,000 | +4.3% | 7,418,153 | +1.5% | 0.56% | -4.9% |
| Q3 2022 | $1,886,877,000 | +5.8% | 7,305,264 | +3.8% | 0.59% | +13.0% |
| Q2 2022 | $1,784,193,000 | -12.8% | 7,037,684 | +0.9% | 0.52% | +2.5% |
| Q1 2022 | $2,046,354,000 | -26.8% | 6,976,285 | -17.9% | 0.51% | -19.6% |
| Q4 2021 | $2,796,677,000 | +26.5% | 8,500,278 | +17.1% | 0.64% | +9.3% |
| Q3 2021 | $2,210,528,000 | +13.1% | 7,260,965 | -0.3% | 0.58% | +12.1% |
| Q2 2021 | $1,954,466,000 | +28.2% | 7,283,001 | +7.5% | 0.52% | +17.4% |
| Q1 2021 | $1,525,122,000 | -3.0% | 6,775,908 | -4.3% | 0.44% | -2.6% |
| Q4 2020 | $1,572,875,000 | +2.9% | 7,080,554 | -0.2% | 0.46% | -16.5% |
| Q3 2020 | $1,527,911,000 | +28.2% | 7,095,676 | +5.3% | 0.54% | +15.2% |
| Q2 2020 | $1,192,121,000 | +28.6% | 6,741,634 | +0.6% | 0.47% | +6.1% |
| Q1 2020 | $927,352,000 | -11.1% | 6,700,023 | -1.4% | 0.45% | +18.6% |
| Q4 2019 | $1,043,024,000 | +7.9% | 6,795,841 | +1.6% | 0.38% | -1.3% |
| Q3 2019 | $966,225,000 | -0.4% | 6,689,917 | -1.5% | 0.38% | -2.3% |
| Q2 2019 | $970,431,000 | +5.9% | 6,790,035 | -2.2% | 0.39% | -0.3% |
| Q1 2019 | $916,427,000 | +29.8% | 6,941,578 | +1.4% | 0.39% | +15.3% |
| Q4 2018 | $706,050,000 | +15.0% | 6,846,878 | +21.6% | 0.34% | +32.9% |
| Q3 2018 | $614,017,000 | +18.2% | 5,630,614 | +7.0% | 0.26% | +9.4% |
| Q2 2018 | $519,338,000 | +6.0% | 5,262,842 | +5.2% | 0.23% | +5.9% |
| Q1 2018 | $489,810,000 | +10.8% | 5,002,676 | +5.0% | 0.22% | +13.4% |
| Q4 2017 | $442,174,000 | +9.8% | 4,763,753 | +1.5% | 0.19% | +0.5% |
| Q3 2017 | $402,741,000 | +3.8% | 4,695,056 | +2.1% | 0.19% | -3.5% |
| Q2 2017 | $387,948,000 | +14.5% | 4,597,093 | +16.1% | 0.20% | +9.9% |
| Q1 2017 | $338,683,000 | +21.2% | 3,959,823 | +10.3% | 0.18% | +20.5% |
| Q4 2016 | $279,375,000 | +7.9% | 3,589,097 | +8.6% | 0.15% | +3.4% |
| Q3 2016 | $259,036,000 | -13.8% | 3,304,458 | +11.1% | 0.15% | -18.4% |
| Q2 2016 | $300,505,000 | +40.1% | 2,975,299 | +31.5% | 0.18% | +34.6% |
| Q1 2016 | $214,556,000 | +15.6% | 2,261,818 | +13.1% | 0.13% | +9.0% |
| Q4 2015 | $185,679,000 | +61.8% | 1,999,121 | +48.5% | 0.12% | +41.9% |
| Q3 2015 | $114,738,000 | +10.6% | 1,346,514 | +11.0% | 0.09% | +19.4% |
| Q2 2015 | $103,781,000 | -1.9% | 1,212,540 | -2.7% | 0.07% | -2.7% |
| Q1 2015 | $105,822,000 | -21.4% | 1,246,433 | -20.6% | 0.07% | -14.9% |
| Q4 2014 | $134,603,000 | +57.4% | 1,570,435 | +39.5% | 0.09% | +50.0% |
| Q3 2014 | $85,530,000 | +19.3% | 1,125,668 | +23.6% | 0.06% | +18.4% |
| Q2 2014 | $71,701,000 | +46.8% | 910,720 | +39.8% | 0.05% | +36.1% |
| Q1 2014 | $48,850,000 | -60.8% | 651,342 | -59.7% | 0.04% | -59.1% |
| Q4 2013 | $124,690,000 | +110.2% | 1,615,134 | +88.7% | 0.09% | +91.3% |
| Q3 2013 | $59,323,000 | +40.6% | 855,791 | +28.4% | 0.05% | +27.8% |
| Q2 2013 | $42,185,000 | – | 666,433 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |